Vamvakides A
Laboratoires CHROPI, Paris.
Ann Pharm Fr. 1990;48(6):312-20.
Convulsions induced on mice by a dose of 200 mg/kg i.p. of amantadine (Ama) or 1-adamantylcyclopentanamine (Ad1) were studied with tricyclic antidepressants (imipramine, desipramine, chlorimipramine), possessing antiglutamatergic properties, or with GABA-linoleamide, a centrally acting GABAergic drug, or with glycine-linoleamide, a centrally acting glycinergic drug, or with glutamic acid palmitamide, a centrally acting glutamatergic drug. The results of these studies could suggest the existence of important glutamatergic and anti-GABAergic components and, probably, of a slight antiglycinergic activity in the pharmacological action profile of the Ad1. Moderate glutamatergic and anti-GABAergic components could operate in the Ama's mechanism of action.
用具有抗谷氨酸能特性的三环类抗抑郁药（丙咪嗪、地昔帕明、氯米帕明），或中枢作用的γ-氨基丁酸能药物γ-亚麻酰胺，或中枢作用的甘氨酸能药物甘氨酸-亚麻酰胺，或中枢作用的谷氨酸能药物谷氨酸棕榈酰胺，研究了腹腔注射200mg/kg金刚烷胺（Ama）或1-金刚烷基环戊胺（Ad1）对小鼠诱发的惊厥。这些研究结果可能提示在Ad1的药理作用谱中存在重要的谷氨酸能和抗γ-氨基丁酸能成分，可能还有轻微的抗甘氨酸能活性。适度的谷氨酸能和抗γ-氨基丁酸能成分可能在Ama的作用机制中起作用。
